ArticleMolecular diversity2020
Synthesis of spirooxindolocarbamates based on Betti reaction: antibacterial, antifungal and antioxidant activities.
Article in Molecular diversity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Spirooxindole 5-(Trifluoromethyl)benzothiazole Hybrids: Synthesis, Crystal Structure, and Antioxidant Activity.Archiv der Pharmazie · 2026Article
- Synthetic advances, pharmacological prospects, and molecular insights of spirooxindoles: a comprehensive review.Journal of molecular modeling · 2026Review
- Therapeutic potential of spiro compounds againstRSC medicinal chemistry · 2025Review
- Design and synthesis of novel quinazolinyl-bisspirooxindoles as potent anti-tubercular agents: an ultrasound-promoted methodology.Molecular diversity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A series of new spirooxindolocarbamates 4a-l and 6a-d were synthesized by using the Betti reaction. All the target compounds were well characterized by IR, NMR and mass spectrometry. The structures of the compounds 4a and 4e were confirmed by the single crystal X-ray diffraction. The in vitro antibacterial activity results revealed that the compounds 4f exhibited excellent antibacterial activity against E. coli with MIC value 7.5 µg/mL when compared with the standard drug ciprofloxacin with MIC value 9.25 µg/mL. The compounds 4l and 6c exhibit significant inhibiting activity against E. Coli with MIC values 10.5 µg/mL and 9.5 µg/mL, respectively. The compounds 4c and 4e showed significant activity against S. aureus with MIC value 10.5 µg/mL. The compounds 4a and 4f were exhibited moderate antifungal activity against A. niger with MIC values 17.5 µg/mL and 18.0 µg/mL, respectively. The compounds 4f and 4l exhibited the potent antioxidant activity with IC
Indexed as
Identifiers
31828569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.